1. Scrip
  2. >>Therapy Areas

Mixed Responses To BioCryst's Oral Phase III HAI Therapy, BCX7353

 
• By John Davis

BioCryst’s BCX7353 could be the first oral therapy to prevent hereditary angioedema attacks, but it might not work in all patients, according to data from the Phase III APeX-2 study.

Allergic
Angioedema can cause swelling in different parts of the body. • Source: Shutterstock.

A lower than expected efficacy rate for BioCryst Pharmaceuticals Inc.’s oral therapy for the prevention of hereditary angioedema, BCX7353, in the pivotal Phase III APeX-2 study, appears to have been key to the US biotech’s share price halving on 21 May, even though the kallikrein inhibitor met its primary endpoints in the study.

BCX7353 has the potential to become the first oral therapy to prevent hereditary angioedema attacks (HAEs), and “we believe BCX7353 is positioned to become a front-line therapy option,” commented

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.